Previous 10 | Next 10 |
2023-11-07 06:04:37 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal Pharmaceuticals raises its FY outlook Amneal to reorganize and simplify corporate structure Seeking Alpha’s Quant Rating on Amn...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Amneal Pharmaceuticals Inc. Class A (AMRX) is expected to report $0.1 for Q3 2023
2023-11-06 11:32:09 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, before market open. The consensus EPS Estimate is $0.13 (-7.1% Y/Y) and the consensus Revenue Estimate is $604.53M (+10.8% Y/Y). Over the...
2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...
2023-10-23 16:23:28 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Amneal to reorganize and simplify corporate structure Amneal gets approval for generic injectable on FDA's shortage list For further details ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023. The Company also raised its financial guidance for the year ending December 31, 2023,...
2023-10-17 16:34:51 ET Amneal Pharmaceuticals ( NYSE: AMRX ) said that it plans to reorganize and simplify its corporate structure, which includes eliminating its umbrella partnership-C-corporation structure. The biotech company said it intends to convert to a more traditional c...
- Biosimilar candidates referencing Prolia ® and XGEVA ® - Builds on first year success of Amneal’s initial three biosimilar launches - Expands existing biosimilar partnership with mAbxience Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Am...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Fourth ESG Report Details Company’s Progress Towards Environmental Sustainability and Contributions Toward Building Healthier Communities as a Leading Provider of Accessible Medicines Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Companyȁ...
The Company’s leading R&D capabilities and robust, expanded manufacturing capacity are helping to address chronic market shortages Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of it...
Significantly expanding access to affordable, life-saving opioid overdose rescue medicine Entered distribution agreement with California; actively engaging with other states and municipalities to expand access Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” o...